Gainers Moxian, Inc. (NASDAQ: MOXC) shares rose 114.9 percent to $0.8166 after the company announced a strategic partnership with Fujian. Bio-Path Holdings, Inc. (NASDAQ: BPTH)...
Gainers Ultra Petroleum Corp (NASDAQ: UPL) shares rose 50.1 percent to $1.15 in pre-market trading after a court ruling was reversed which would have forced the company to pay...
Some of the stocks that may grab investor focus today are: Wall Street expects Schlumberger Limited (NYSE: SLB) to report quarterly earnings at $0.37 per share on revenue of $8.12...
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) incurred fourth-quarter 2018 loss of $1.58 per share, narrower than the Zacks Consensus Estimate of a loss of $1.65 and also the...
Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced fourth-quarter 2018 earnings per share of 45 cents, significantly beating the Zacks Consensus Estimate of a loss of 60 cents....
In January 2019, Sunesis Pharmaceuticals (NASDAQ:SNSS) announced that its Phase Ib/II study of vecabrutinib for B-cell cancers advanced to the 100mg cohort. The company experienced...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Buy||Buy||Buy||Buy||Strong Sell|
|Technical Indicators||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Sell|
|Summary||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Doji Star Bearish||1H||Current|
|Harami Cross Bearish||1H||Current|
|Belt Hold Bearish||1D||Current|
|Engulfing Bearish||30||1||Feb 19, 2019 03:00PM|
|Evening Doji Star||30||1||Feb 19, 2019 03:00PM|
|Evening Star||30||1||Feb 19, 2019 03:00PM|
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.Read More
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||$250||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.